Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy
Claudia Brandt, Patricia Seja, Kathrin Töllner, Kerstin Römermann, Philip Hampel, Markus Kalesse, Andi Kipper, Peter W Feit, Kasper Lykke, Trine Lisberg Toft-Bertelsen, Pauliina Paavilainen, Inkeri Spoljaric, Martin Puskarjov, Nanna MacAulay, Kai Kaila, Wolfgang Löscher
Dive into the research topics of 'Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy'. Together they form a unique fingerprint.